Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 10.9Regular26.10.10 02:308-KKey event#●●●
Vogenx, Inc.
Vogenx has appointed board member Richard Gorman as Chief Commercial Officer, effective October 12, 2026. Concurrently, Mr. Gorman will resign from his position on the Board of Directors and all its committees, and the company will initiate a search for a new independent director.…more
$17.11-2.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:584Ownership
Vogenx, Inc.
Insider William Wilkison of Vogenx, Inc. reported a change in beneficial ownership of securities as of October 2, 2026. This filing serves as the official disclosure of the insider's equity position change via Form 4.…more
$17.11-2.00%vs prev closeView filingShare - 10.6After-hours26.10.07 05:574Ownership
Vogenx, Inc.
Insider Kenneth John Toombs of Vogenx, Inc. reported a change in his beneficial ownership of securities as of October 2, 2026. This filing formalizes the insider's transaction details via Form 4.…more
$17.11-2.00%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15After-hours26.10.16 05:37#●●●#●●●#●●●
Vogenx Initiates Phase 2b Clinical Trial for Post-Bariatric Hypoglycemia Treatment…more
Vogenx has initiated a Phase 2b clinical trial for its investigational drug, mizagliflozin, to treat post-bariatric hypoglycemia. As there are currently no FDA-approved therapies for this condition, the trial results will be a key indicator for the company's future market potential.…more
$17.11-2.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga